Engelmar Unzeitig

Recent publications · Crossref

5 total works indexed

1. Whole-genome analysis informs breast cancer response to aromatase inhibition

   · 2012 · cited 881x

2. Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

   · 2011 · cited 470x

3. Cancer Risks Associated With Germline<i>PALB2</i>Pathogenic Variants: An International Study of 524 Families

   · 2020 · cited 377x

4. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

   · 2017 · cited 296x

5. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

   · 2015 · cited 200x

via Crossref · CC0

Wikidata facts